Other languages Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
3.95 ^USD	+4.77%		+16.18%	-55.06%

12:00am	Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	CI
12:00am	Certain Common Stock of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbbVie raises annual profit forecast on strong Skyrizi sales	04-26
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	04-12
Revance Therapeutics Prices $100 Million Public Offering	03-04
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	02-28
Revance Therapeutics, Inc. Announces Executive Changes	02-28
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology	02-02
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	02-02
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling	12-12
US Consumer group seeks stronger warnings on Botox, similar treatments	12-12
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics	11-08
Top Midday Decliners	23-09-19
Revance Therapeutics Forecasts Impairment Charge of Up to $100 Million Amid Restructuring, Opul Exit; Shares Fall	23-09-19
Insider Sell: Revance Therapeutics	23-09-07
'Barbie Botox' goes viral but doctors inject caution	23-09-01
Revance Therapeutics Says US FDA Approved Daxxify for Involuntary Neck Muscle Contraction	23-08-14
Revance's Botox rival gets FDA approval for painful neck muscle condition	23-08-14
U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	23-08-14
Revance Therapeutics' Q2 Net Loss Narrows, Revenue Increases	23-08-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Other languages

Filters